Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML
Trial Parameters
Brief Summary
The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
Eligibility Criteria
Inclusion Criteria: * 1、Newly diagnosed, untreated AML； * 2、Under 18 years old; * 3、Patients who have used hydroxyurea or cytarabine before diagnosis, but the dosage of cytarabine does not exceed 5 days, and the total dose does not exceed 500 mg/m2 (50 mg/m2, q12h × 5d)； * 4、 Liver function：Tbil≤2×ULN, ALT/AST≤3×ULN, creatinine clearance ≥50ml/min；Cardiac NYHA grading\<3；SaO2\>92%; * 5、No active infection (symptoms resolved for more than 3 days if infected) * 6、ECOG\<2; * 7、Expected survival time greater than 12 weeks; * 9、Obtain the consent of the child and/or guardian and sign the informed consent form. Exclusion Criteria: * 1、Acute megakaryocytic leukemia (AMKL)； * 2、Acute promyelocytic leukemia (APL); * 3、Treatment-related secondary AML and AML with definite MDS transformation； * 4、Myeloproliferative neoplasm (such as Juvenile myelomonocytic leukemia, JMML); * 5、AML secondary to congenital bone marrow failure (such as AML secondary to Fanconi anemia (FA)； * 6、AML secondary to Down